West Pharmaceutical Services Expects 2024 Adjusted EPS Of $6.35-$6.65 Versus Prior Guidance Of $7.63-$7.88 And Consensus Of $7.74
Portfolio Pulse from Benzinga Newsdesk
West Pharmaceutical Services has revised its 2024 adjusted EPS guidance to $6.35-$6.65, down from the previous guidance of $7.63-$7.88 and below the consensus estimate of $7.74.
July 25, 2024 | 10:05 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
West Pharmaceutical Services has significantly lowered its 2024 adjusted EPS guidance to $6.35-$6.65 from the previous $7.63-$7.88, which is also below the consensus estimate of $7.74.
The significant reduction in EPS guidance indicates potential challenges or lower-than-expected performance for West Pharmaceutical Services. This is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100